Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) Stock Competitors & Peer Comparison
See HKPD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HKPD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HKPD | $0.13 | +3.65% | 1.3M | -2.04 | -$0.06 | N/A |
| MCK | $881.51 | +0.07% | 103.2B | 21.59 | $40.82 | +0.39% |
| COR | $321.57 | +0.19% | 62.6B | 18.75 | $17.15 | +0.75% |
| CAH | $234.57 | -0.61% | 54.9B | 22.49 | $10.43 | +0.87% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $88.36 | +1.21% | 10.1B | 16.64 | $5.31 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +2.49% |
| AHG | $0.84 | +14.93% | 678.6M | -3.72 | -$0.21 | N/A |
| OMI | $2.68 | +8.94% | 207.1M | -0.47 | -$5.69 | N/A |
| EMPG | $17.36 | +0.00% | 143M | 192.89 | $0.09 | N/A |
Stock Comparison
McKesson Corporation (NYSE: MCK)
HKPD vs MCK Comparison September 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 1.3M. In comparison, MCK has a market cap of 103.2B. Regarding current trading prices, HKPD is priced at $0.13 on the NASDAQ, while MCK trades at $881.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -2.04, whereas MCK's P/E ratio is 21.59. In terms of profitability, HKPD's ROE is -0.15%, compared to MCK's ROE of -1.94%. Regarding short-term risk, HKPD is more volatile compared to MCK. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check MCK's competition here
Cencora, Inc. (NYSE: COR)
HKPD vs COR Comparison September 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 1.3M. In comparison, COR has a market cap of 62.6B. Regarding current trading prices, HKPD is priced at $0.13 on the NASDAQ, while COR trades at $321.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -2.04, whereas COR's P/E ratio is 18.75. In terms of profitability, HKPD's ROE is -0.15%, compared to COR's ROE of +1.06%. Regarding short-term risk, HKPD is more volatile compared to COR. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check COR's competition here
Cardinal Health, Inc. (NYSE: CAH)
HKPD vs CAH Comparison September 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 1.3M. In comparison, CAH has a market cap of 54.9B. Regarding current trading prices, HKPD is priced at $0.13 on the NASDAQ, while CAH trades at $234.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -2.04, whereas CAH's P/E ratio is 22.49. In terms of profitability, HKPD's ROE is -0.15%, compared to CAH's ROE of -0.60%. Regarding short-term risk, HKPD is more volatile compared to CAH. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check CAH's competition here
AmerisourceBergen Corporation (NYSE: ABC)
HKPD vs ABC Comparison September 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 1.3M. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, HKPD is priced at $0.13 on the NASDAQ, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -2.04, whereas ABC's P/E ratio is 21.92. In terms of profitability, HKPD's ROE is -0.15%, compared to ABC's ROE of +1.06%. Regarding short-term risk, HKPD is more volatile compared to ABC. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check ABC's competition here
Henry Schein, Inc. (NASDAQ: HSIC)
HKPD vs HSIC Comparison September 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 1.3M. In comparison, HSIC has a market cap of 10.1B. Regarding current trading prices, HKPD is priced at $0.13 on the NASDAQ, while HSIC trades at $88.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -2.04, whereas HSIC's P/E ratio is 16.64. In terms of profitability, HKPD's ROE is -0.15%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, HKPD is more volatile compared to HSIC. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check HSIC's competition here
Patterson Companies, Inc. (NASDAQ: PDCO)
HKPD vs PDCO Comparison September 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 1.3M. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, HKPD is priced at $0.13 on the NASDAQ, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -2.04, whereas PDCO's P/E ratio is 20.48. In terms of profitability, HKPD's ROE is -0.15%, compared to PDCO's ROE of +0.18%. Regarding short-term risk, HKPD is more volatile compared to PDCO. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check PDCO's competition here
Akso Health Group (NASDAQ: AHG)
HKPD vs AHG Comparison September 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 1.3M. In comparison, AHG has a market cap of 678.6M. Regarding current trading prices, HKPD is priced at $0.13 on the NASDAQ, while AHG trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -2.04, whereas AHG's P/E ratio is -3.72. In terms of profitability, HKPD's ROE is -0.15%, compared to AHG's ROE of -0.50%. Regarding short-term risk, HKPD is less volatile compared to AHG. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check AHG's competition here
Owens & Minor, Inc. (NYSE: OMI)
HKPD vs OMI Comparison September 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 1.3M. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, HKPD is priced at $0.13 on the NASDAQ, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -2.04, whereas OMI's P/E ratio is -0.47. In terms of profitability, HKPD's ROE is -0.15%, compared to OMI's ROE of +0.63%. Regarding short-term risk, HKPD is less volatile compared to OMI. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check OMI's competition here
Empro Group Inc. Ordinary shares (NASDAQ: EMPG)
HKPD vs EMPG Comparison September 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 1.3M. In comparison, EMPG has a market cap of 143M. Regarding current trading prices, HKPD is priced at $0.13 on the NASDAQ, while EMPG trades at $17.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -2.04, whereas EMPG's P/E ratio is 192.89. In terms of profitability, HKPD's ROE is -0.15%, compared to EMPG's ROE of +0.66%. Regarding short-term risk, HKPD is more volatile compared to EMPG. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check EMPG's competition here
Accendra Health, Inc. (NYSE: ACH)
HKPD vs ACH Comparison September 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 1.3M. In comparison, ACH has a market cap of 82.7M. Regarding current trading prices, HKPD is priced at $0.13 on the NASDAQ, while ACH trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -2.04, whereas ACH's P/E ratio is 1.59. In terms of profitability, HKPD's ROE is -0.15%, compared to ACH's ROE of +0.63%. Regarding short-term risk, HKPD is more volatile compared to ACH. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check ACH's competition here
Akso Health Group (NASDAQ: HX)
HKPD vs HX Comparison September 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 1.3M. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, HKPD is priced at $0.13 on the NASDAQ, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -2.04, whereas HX's P/E ratio is -1.84. In terms of profitability, HKPD's ROE is -0.15%, compared to HX's ROE of -1.07%. Regarding short-term risk, HKPD is more volatile compared to HX. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check HX's competition here
111, Inc. (NASDAQ: YI)
HKPD vs YI Comparison September 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 1.3M. In comparison, YI has a market cap of 31.1M. Regarding current trading prices, HKPD is priced at $0.13 on the NASDAQ, while YI trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -2.04, whereas YI's P/E ratio is -2.54. In terms of profitability, HKPD's ROE is -0.15%, compared to YI's ROE of +0.14%. Regarding short-term risk, HKPD is less volatile compared to YI. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check YI's competition here
Wellgistics Health, Inc. (NASDAQ: WGRX)
HKPD vs WGRX Comparison September 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 1.3M. In comparison, WGRX has a market cap of 8.7M. Regarding current trading prices, HKPD is priced at $0.13 on the NASDAQ, while WGRX trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -2.04, whereas WGRX's P/E ratio is -0.33. In terms of profitability, HKPD's ROE is -0.15%, compared to WGRX's ROE of +8.78%. Regarding short-term risk, HKPD is less volatile compared to WGRX. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check WGRX's competition here
Zynex, Inc. (NASDAQ: ZYXI)
HKPD vs ZYXI Comparison September 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 1.3M. In comparison, ZYXI has a market cap of 3.8M. Regarding current trading prices, HKPD is priced at $0.13 on the NASDAQ, while ZYXI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -2.04, whereas ZYXI's P/E ratio is -0.05. In terms of profitability, HKPD's ROE is -0.15%, compared to ZYXI's ROE of +11.38%. Regarding short-term risk, HKPD is more volatile compared to ZYXI. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check ZYXI's competition here
DataMEDS AI, Inc. (NASDAQ: MEDS)
HKPD vs MEDS Comparison September 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 1.3M. In comparison, MEDS has a market cap of 2.4M. Regarding current trading prices, HKPD is priced at $0.13 on the NASDAQ, while MEDS trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -2.04, whereas MEDS's P/E ratio is N/A. In terms of profitability, HKPD's ROE is -0.15%, compared to MEDS's ROE of +8.78%. Regarding short-term risk, HKPD is more volatile compared to MEDS. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check MEDS's competition here
Synergy CHC Corp. (NASDAQ: SNYR)
HKPD vs SNYR Comparison September 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 1.3M. In comparison, SNYR has a market cap of 1.1M. Regarding current trading prices, HKPD is priced at $0.13 on the NASDAQ, while SNYR trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -2.04, whereas SNYR's P/E ratio is -0.07. In terms of profitability, HKPD's ROE is -0.15%, compared to SNYR's ROE of +0.91%. Regarding short-term risk, HKPD is less volatile compared to SNYR. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check SNYR's competition here
Ridgetech, Inc. (NASDAQ: RDGT)
HKPD vs RDGT Comparison September 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 1.3M. In comparison, RDGT has a market cap of 745.1K. Regarding current trading prices, HKPD is priced at $0.13 on the NASDAQ, while RDGT trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -2.04, whereas RDGT's P/E ratio is -0.02. In terms of profitability, HKPD's ROE is -0.15%, compared to RDGT's ROE of -0.04%. Regarding short-term risk, HKPD is more volatile compared to RDGT. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check RDGT's competition here
Covetrus, Inc. (NASDAQ: CVET)
HKPD vs CVET Comparison September 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 1.3M. In comparison, CVET has a market cap of 0. Regarding current trading prices, HKPD is priced at $0.13 on the NASDAQ, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -2.04, whereas CVET's P/E ratio is -69.97. In terms of profitability, HKPD's ROE is -0.15%, compared to CVET's ROE of -0.06%. Regarding short-term risk, HKPD is more volatile compared to CVET. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check CVET's competition here